Michael C Sneller

Summary

Affiliation: National Institutes of Health
Country: USA

Publications

  1. ncbi A randomized controlled trial of rituximab following failure of antiviral therapy for hepatitis C virus-associated cryoglobulinemic vasculitis
    Michael C Sneller
    Laboratory of Immunoregulation, National Institute of Allergy and Infectious Diseases, NIH, Bethesda, MD 20854, USA
    Arthritis Rheum 64:835-42. 2012
  2. ncbi Granuloma formation, implications for the pathogenesis of vasculitis
    Michael C Sneller
    Laboratory of Immunoregulation, National Institute of Allergy, Immunology, and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA
    Cleve Clin J Med 69:SII40-3. 2002
  3. ncbi Autoimmune lymphoproliferative syndrome
    Michael C Sneller
    Immunologic Diseases Section, Laboratory of Immunoregulation, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland 20892, USA
    Curr Opin Rheumatol 15:417-21. 2003
  4. ncbi Mycophenolate mofetil for remission maintenance in the treatment of Wegener's granulomatosis
    Carol A Langford
    National Institute of Allergy and Infectious Diseases, NIH, Bethesda, Maryland, USA
    Arthritis Rheum 51:278-83. 2004
  5. ncbi CT virtual bronchoscopy of the central airways in patients with Wegener's granulomatosis
    Ronald M Summers
    Diagnostic Radiology Department, Warren Grant Magnuson Clinical Center, National Institutes of Health, Bethesda, MD 20892 1182, USA
    Chest 121:242-50. 2002
  6. ncbi Safety (toxicity), pharmacokinetics, immunogenicity, and impact on elements of the normal immune system of recombinant human IL-15 in rhesus macaques
    Thomas A Waldmann
    Center for Cancer Research, National Cancer Institute, Frederick, MD, USA
    Blood 117:4787-95. 2011
  7. ncbi Severe chronic graft-versus-host disease is characterized by a preponderance of CD4(+) effector memory cells relative to central memory cells
    Kouhei Yamashita
    Laboratory of Host Defenses, National Institutes of Allergy and Infectious Diseases, National Institutes of Health NIH, Bethesda, MD 20892 1886, USA
    Blood 103:3986-8. 2004
  8. ncbi Tarsal-conjunctival disease associated with Wegener's granulomatosis
    Michael R Robinson
    National Eye Institute, National Institutes of Health, Bethesda, Maryland, USA
    Ophthalmology 110:1770-80. 2003
  9. ncbi B cell homeostasis in chronic hepatitis C virus-related mixed cryoglobulinemia is maintained through naïve B cell apoptosis
    Lauren E Holz
    Liver Diseases Branch, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD, USA
    Hepatology 56:1602-10. 2012
  10. ncbi Use of a cyclophosphamide-induction methotrexate-maintenance regimen for the treatment of Wegener's granulomatosis: extended follow-up and rate of relapse
    Carol A Langford
    National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland 20892, USA
    Am J Med 114:463-9. 2003

Detail Information

Publications14

  1. ncbi A randomized controlled trial of rituximab following failure of antiviral therapy for hepatitis C virus-associated cryoglobulinemic vasculitis
    Michael C Sneller
    Laboratory of Immunoregulation, National Institute of Allergy and Infectious Diseases, NIH, Bethesda, MD 20854, USA
    Arthritis Rheum 64:835-42. 2012
    ..To perform a randomized controlled trial of rituximab in patients with hepatitis C virus (HCV)-associated mixed cryoglobulinemic vasculitis...
  2. ncbi Granuloma formation, implications for the pathogenesis of vasculitis
    Michael C Sneller
    Laboratory of Immunoregulation, National Institute of Allergy, Immunology, and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA
    Cleve Clin J Med 69:SII40-3. 2002
    ..A better understanding of these events will allow us to more precisely modulate the granulomatous inflammatory response to the benefit of patients with both infectious and autoimmune diseases...
  3. ncbi Autoimmune lymphoproliferative syndrome
    Michael C Sneller
    Immunologic Diseases Section, Laboratory of Immunoregulation, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland 20892, USA
    Curr Opin Rheumatol 15:417-21. 2003
    ..Prospective evaluations of patients and their families have revealed an ever-expanding spectrum of autoimmune lymphoproliferative syndrome and its major complications...
  4. ncbi Mycophenolate mofetil for remission maintenance in the treatment of Wegener's granulomatosis
    Carol A Langford
    National Institute of Allergy and Infectious Diseases, NIH, Bethesda, Maryland, USA
    Arthritis Rheum 51:278-83. 2004
    ..To examine the safety of mycophenolate mofetil (MMF) for remission maintenance in patients with Wegener's granulomatosis (WG) who had been treated with daily cyclophosphamide (CYC) and glucocorticoids to induce remission...
  5. ncbi CT virtual bronchoscopy of the central airways in patients with Wegener's granulomatosis
    Ronald M Summers
    Diagnostic Radiology Department, Warren Grant Magnuson Clinical Center, National Institutes of Health, Bethesda, MD 20892 1182, USA
    Chest 121:242-50. 2002
    ..To compare CT virtual bronchoscopy (VB) to CT alone and to conventional bronchoscopy for evaluation of central airway stenoses in patients with Wegener's granulomatosis...
  6. ncbi Safety (toxicity), pharmacokinetics, immunogenicity, and impact on elements of the normal immune system of recombinant human IL-15 in rhesus macaques
    Thomas A Waldmann
    Center for Cancer Research, National Cancer Institute, Frederick, MD, USA
    Blood 117:4787-95. 2011
    ....
  7. ncbi Severe chronic graft-versus-host disease is characterized by a preponderance of CD4(+) effector memory cells relative to central memory cells
    Kouhei Yamashita
    Laboratory of Host Defenses, National Institutes of Allergy and Infectious Diseases, National Institutes of Health NIH, Bethesda, MD 20892 1886, USA
    Blood 103:3986-8. 2004
    ..This finding implies that overrepresentation of CD4(EM) cells is a unique feature of cGVHD...
  8. ncbi Tarsal-conjunctival disease associated with Wegener's granulomatosis
    Michael R Robinson
    National Eye Institute, National Institutes of Health, Bethesda, Maryland, USA
    Ophthalmology 110:1770-80. 2003
    ..To describe the clinical characteristics of tarsal-conjunctival disease in a cohort of patients with Wegener's granulomatosis (WG)...
  9. ncbi B cell homeostasis in chronic hepatitis C virus-related mixed cryoglobulinemia is maintained through naïve B cell apoptosis
    Lauren E Holz
    Liver Diseases Branch, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD, USA
    Hepatology 56:1602-10. 2012
    ..Conclusion: This study provides insight into the mechanisms maintaining B cell homeostasis in HCV-induced MC and the ability of rituximab therapy to restore normal B cell compartments. (HEPATOLOGY 2012;56:1602-1610)...
  10. ncbi Use of a cyclophosphamide-induction methotrexate-maintenance regimen for the treatment of Wegener's granulomatosis: extended follow-up and rate of relapse
    Carol A Langford
    National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland 20892, USA
    Am J Med 114:463-9. 2003
    ..To determine the relapse rate and outcome in patients with Wegener's granulomatosis treated with daily cyclophosphamide and glucocorticoids to induce remission followed by methotrexate for remission maintenance...
  11. ncbi Pathogenesis of Wegener's granulomatosis: current concepts
    Pasha Sarraf
    Immunologic Diseases Section, Laboratory of Immunoregulation, National Institute of Allergy and Infectious Diseases, NIH, Bethesda, MD 20892 1876, USA
    Expert Rev Mol Med 7:1-19. 2005
    ..Future animal models of this disease will have to account for the role of both ANCA-mediated pathology and granulomatous inflammation to enable us to understand the chronic and persistent features of WG in humans...
  12. ncbi Biologic therapies in the vasculitides
    Carol A Langford
    Immunologic Diseases Section, Laboratory of Immunoregulation, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland 20892, USA
    Curr Opin Rheumatol 15:3-10. 2003
    ..In the research setting, investigation of biologic agents in the treatment of vasculitic diseases may also provide important insights into pathogenesis of these syndromes...
  13. ncbi A multicenter, randomized, double-blind, placebo-controlled trial of adjuvant methotrexate treatment for giant cell arteritis
    Gary S Hoffman
    Cleveland Clinic Foundation, Cleveland, Ohio 44915, USA
    Arthritis Rheum 46:1309-18. 2002
    ....
  14. ncbi Rituximab and Wegener's granulomatosis: are B cells a target in vasculitis treatment?
    Michael C Sneller
    Arthritis Rheum 52:1-5. 2005